Envisagenics

This Lung Cancer Awareness Month, we honor the resilience of patients and families impacted by lung cancer and recognize the vital work of researchers and healthcare professionals dedicated to finding innovative solutions. At Envisagenics, we are committed to advancing RNA-based technologies to uncover new therapeutics for cancer, including NSCLC. Together, we can raise awareness, support early detection, and drive breakthroughs in treatment. #LungCancerAwarenessMonth #NSCLC #InnovationInHealthcare #Envisagenics

On World Pancreatic Cancer Day, we stand in solidarity with patients, families, and researchers dedicated to fighting this challenging disease. At Envisagenics, we are committed to advancing RNA-based solutions that can help pave the way for more effective treatments. Together, let’s raise awareness and work towards breakthroughs in early detection and therapies. #WorldPancreaticCancerDay #PancreaticCancerAwareness #Envisagenics

We are excited to have Maria Luisa Pineda, PhD., our CEO and co-founder, to be part of the panel "Our AI Future: A Sector-by-Sector Breakdown", where we'll explore the latest trends, challenges, and opportunities surrounding AI-driven advancements in biotech, medtech, and pharma. As AI and machine learning continue to transform the industry, we’ll dive into how these technologies are streamlining processes—from drug discovery to medical device development—and share real-world examples of their impact on patient care. The panel will be moderated by?Zoey Becker, Staff Writer at?Fierce Pharma, and will feature esteemed speakers, including:?Sreenu Prakash Sai Jasti, Head of Data Science & Artificial Intelligence at?Bayer Pharmaceuticals R&D?and?Lars Fogh Iversen, PhD, Senior Vice President, Digital Science & Innovation at?Novo Nordisk. Don't miss this deep dive into the future of AI in healthcare! #AI #JPM2025 #Biotech #MedTech #Pharma #AIinHealthcare

Miguel A. Manzanares, Principal Scientist at Envisagenics, will be a part the?Dagstuhl Seminar 24491: Deep Learning for RNA Regulation and Multidimensional Transcriptomics at Schloss Dagstuhl – Leibniz-Zentrum für Informatik (LZI), Germany, on?Thursday, Dec. 5th. His talk will delve into?RNA in Disease and RNA Therapeutics, showcasing cutting-edge advancements in RNA biology and its therapeutic applications. We’re proud to contribute to the conversation shaping the future of RNA research and its therapeutic potential. #RNAInnovation #RNATherapeutics #Biotech #Envisagenics #DagstuhlSeminar

Co-founders of Envisagenics,?Martin Akerman and Maria Luisa Pineda, PhD., were honored to attend the Prix Galien USA 2024 Awards Ceremony, celebrating the pioneers advancing healthcare through groundbreaking biopharma and medtech innovation. Inspired by this year’s achievements, we look forward to next year’s continued contributions to scientific excellence. #PrixGalien #HealthcareInnovation #ExcellenceInScience

Envisagenics is proud to sponsor and participate in The Tulane AI & Healthcare Design Lab, a unique 3.5-day program dedicated to advancing healthcare innovation through the Biodesign process. This event brings together a select group of 32 top students, clinicians, and early-career professionals from across the nation to address critical healthcare challenges through AI-driven solutions. Participants will engage in intensive, hands-on workshops and team-based learning with guidance from leading experts, culminating in a high-impact pitch session before venture capitalists. We’re excited to support this next generation of innovators at the intersection of healthcare and technology. Tulane University #AIinHealthcare #Biodesign #HealthcareInnovation #Envisagenics

We had a very interesting panel discussion yesterday afternoon at BIO-Europe, “I Have a Dream”: AI for drug discovery. Thank you to Maria Luisa Pineda, PhD., Lovisa Afzelius, Stephan Brock, Michelle Chen, Tim James, Prof. Dr. Hartmut Juhl, Nikolaus Krall and Rogier Rooswinkel for sharing your knowledge on how AI algorithms are reshaping the landscape, accelerating the identification and development of novel therapeutics. #BIOEurope #AI #DrugDiscovery

Today, we honor the bravery, sacrifice, and dedication of our veterans. At Envisagenics, we recognize the profound impact of these men and women, not only in safeguarding our freedoms but also in inspiring us to pursue innovation and resilience. To all who have served, we thank you and your families for your service and commitment. Happy Veterans Day. #VeteransDay #ThankYouVeterans #Envisagenics

Envisagenics is honored to have participated in BIO-Europe 2024 in Stockholm, an event hosted by EBD Group and the Biotechnology Innovation Organization that brings together leaders from across the biotech industry. It was a privilege to connect with partners and innovators advancing the field of RNA therapeutics and beyond. A highlight of the event was the panel discussion,?"I Have a Dream: AI for Drug Discovery,"?moderated by our Co-Founder and CEO, Maria Luisa Pineda, PhD.. Maria led an insightful discussion with industry leaders, including Prof. Dr. Hartmut Juhl from Indivumed Therapeutics, Lovisa Afzelius from Flagship Pioneering, Stephan Brock from Molecular Health, Michelle Chen from Insilico Medicine, Tim James from Evotec, Nikolaus Krall from Exscientia, and Rogier Rooswinkel from Forbion, examining the current and future impact of AI in reshaping drug discovery. Thank you to all who engaged with us at BIO-Europe. We’re looking forward to building on the momentum of these conversations to drive forward innovation in biotech. #BIOEurope2024 #BiotechInnovation #RNATherapeutics #Envisagenics #Partnerships

We extend our sincere gratitude to everyone who participated in the "I Have a Dream" panel on AI for Drug Discovery at BIO-Europe 2024, moderated by our?Co-Founder and CEO, Maria Luisa Pineda, PhD.. It was a privilege to engage with such accomplished leaders, including: Prof. Dr. Hartmut Juhl, CEO, Indivumed Therapeutics Lovisa Afzelius, General Partner, Flagship Pioneering Stephan Brock, CEO, Molecular Health Michelle Chen, Chief Business Officer, Insilico Medicine Tim James, VP - Head of In Silico R&D, Evotec Nikolaus Krall, EVP Precision Medicine, Exscientia Rogier Rooswinkel, General Partner, Forbion Thank you for contributing to a truly impactful discussion, and we look forward to continued collaboration in advancing biotech innovation. EBD Group Biotechnology Innovation Organization #BIOEurope2024 #AIDrugDiscovery #BiotechInnovation #Envisagenics